iCubate begins clinical study of new bloodstream bacteria detector

iCubate Inc., a biotechnology company at the HudsonAlpha Institute for Biotechnology, has begun clinical studies of a product to detect the most common cause of bacterial bloodstream infections.

The test would identify gram-positive bacteria such as staphylococcus, which are common bacterial blood contaminants. Earlier Beta testing at three laboratories verified the product’s performance, the company said.

“In order to provide the best treatment to patients, physicians need an accurate diagnosis,” iCubate founder and chairman Dr. Jian Han said in a statement today. “iCubate will provide this using groundbreaking multiplex technology and an innovative platform.”

The company says its disposable test cassette will detect multiple pathogens and antibiotic resistance markers.

“This is significant milestone in our young company’s growth. We look forward to moving ahead toward clinical approval…,” iCubate CEO Carter Wells said in the statement.

Share:

0

Get more info now!

iCubate® Technology Creates a Unique, One-Step Multiplex PCR MDx Platform which has the ability to perform simple extraction, amplification, and detection, all in a multiplexed, automated, and closed system.